Overview
Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Skin Cancer
Status:
Unknown status
Unknown status
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may be an effective treatment against skin cancer. PURPOSE: This phase II trial is studying the side effects of photodynamic therapy using aminolevulinic acid and to see how well it works in treating patients with skin cancer.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Laser and Skin Surgery Center of New YorkTreatments:
Aminolevulinic Acid
Criteria
DISEASE CHARACTERISTICS:- Biopsy-proven basal cell carcinoma on the trunk or extremities
- Tumor size ≤ 2 cm in diameter
PATIENT CHARACTERISTICS:
- Willing and able to comply with all follow-up requirements
- Mentally competent
- No active, localized, or systemic infections
- Not immunocompromised
- No coagulation disorder
- No photosensitivity or allergy to sunlight
- Not pregnant or nursing
- No history of keloid formation
- No history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins,
or photodermatosis
PRIOR CONCURRENT THERAPY:
- No prior gold therapy
- No prior radiotherapy to the trunk and extremities
- More than 24 months since prior oral retinoids (e.g., isotretinoin or acitretin) or
photosensitizing drugs (e.g., Declomycin®)
- More than 1 year since prior collagen or other injections, Botox® injections, chemical
peels, dermabrasion, or resurfacing procedures
- More than 1 month since prior topical retinoid therapy
- No concurrent aspirin or antioxidants
- No concurrent anticoagulation medications